CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients

European Journal of Clinical Pharmacology

Volumn 64, Issue 1, 2008, Pages 9-15

  Lima, M V ^a   Ribeiro, G S ^a   Mesquita, E T ^a   Victer, P R ^a   Vianna Jorge, R ^b,c  

^a HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Brazilians; CYP2C9; Gene polymorphism; Warfarin

Indexed keywords

AMIODARONE; CYTOCHROME P450 2C9; OMEPRAZOLE; SIMVASTATIN; WARFARIN;

ADOLESCENT; ADULT; AGED; ALCOHOL ABUSE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAZILIAN; CHILD; CLINICAL FEATURE; COLLAGEN DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG INDICATION; DRUG METABOLISM; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HISPANIC; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LIVER DISEASE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL ANALYSIS; THROMBOEMBOLISM; THYROID DISEASE; VALVULAR HEART DISEASE; VOLUNTEER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BRAZIL; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENOTYPE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MODELS, GENETIC; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK; WARFARIN;

EID: 38049092618     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0385-2     Document Type: Article

References (31)

1. Brummel KE, Paradis SG, Branda RF, Mann KG et al (2001) Oral anticoagulation thresholds. Circulation 104(19):2311-2317
2. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119(1 Suppl):8S-21S
3. Beyth RJ, Quin L, Landefeld CS (2000) A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized controlled trial. Ann Intern Med 133:687-695
4. Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95:315-328
5. Fihn SD, McDonell M, Martin D et al (1993) Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 118(7):511-520
6. Kaminsky LS, Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74
7. Crespi CL, Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH cytochrome P450 oxidoreductase. Pharmacogenetics 7(3):203-210
8. Takahashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K (2000) CYP2C9 Ile 359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10(2):95-104
9. Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A (2005) Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 78(5):540-550
10. Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM (2004) CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 75(3):198-203
11. Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96(5):1816-1819
12. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690-1698
13. Aithal GP, Day CP, Kesteven PJL, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154):717-719
14. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72(6):702-710
15. You JHS, Chan FCW, Wong RSM, Cheng G (2004) The potential clinical and economic outcomes of pharmacogenetics oriented management of warfarin therapy-a decision analysis. J Thromb Haemost 92(3):590-597
16. Schalekamp T, Boink GJJ, Visser LE, Stricker BHC, de Boer A, Klungel OH (2006) CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clin Pharmacol Ther 79(6):511-520
17. Vianna-Jorge J, Perini JA, Rondinelli E, Suarez-Kurtz G (2004) CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther 76(1):18-26
18. Ansell J, Anderson D et al (2001) Managing oral anticoagulant therapy. Chest 119(Suppl1):22S-38S
19. Salazar LA, Hirata MH, Cavalli SA, Machado MO, Hirata RD (1998) Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. Clin Chem 44(8 Pt1):1748-1750
20. 359 allelic variant in tolbutamide polymorphism. Pharmacogenetics 6(4):341-349
21. Verstuyft C, Robert A, Morin S, Loriot MA, Flahault A, Beaune P et al (2003) Genetic and environmental risk factors for oral anticoagulant overdose. Eur J Clin Pharmacol 58(11):739-745
22. Kirchheiner J, Brockmoller J (2005) Clinical consequences of cytochrome P4502C9 polymorphisms. Clin Pharmacol Ther 77(1):1-16
23. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352(22):2285-2293
24. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7):2329-2333
25. Osman A, Enstrom C, Arbring K, Soderkvist P, Lindahl TL (2006) Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. J Thromb Haemost 4(8):1723-1729
26. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie et al (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16(2):101-110
27. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S et al (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5(4):262-270
28. Rost S, Fregin A, Ivaskevicius V et al (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537-541
29. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427:541-544
30. Hamberg A-K, Dahl M-L, Barban M et al (2007) A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 81(4):529-538
31. Limdi NA, McGwin G, Goldstein JA et al (2007) Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther Jul 25 [Epub ahead of print]